帶狀皰疹後神經痛治療市場報告：2031 年趨勢、預測與競爭分析

全球帶狀皰疹後神經痛治療市場前景光明，醫院藥局、線上藥局和零售藥局市場都蘊藏著巨大的機會。預計2025年至2031年期間，全球帶狀皰疹後神經痛治療市場的複合年成長率將達到4.0%。該市場的主要驅動力包括帶狀皰疹發病率的上升、人們對帶狀皰疹後神經痛認知的不斷加深以及先進治療方案的日益普及。

• Lucintel 預測，在類型類別中，抗驚厥藥物預計在預測期內將出現更高的成長。
• 在應用類別中，零售藥局預計將見證最高的成長。
• 從地區來看，預計北美將在預測期內實現最高成長。

帶狀皰疹後神經痛治療市場的新趨勢

帶狀皰疹後神經痛治療市場正在見證一些新興趨勢，這些趨勢正在徹底改變患者的照護和治療。這些趨勢涵蓋技術進步、患者行為和治療模式的改變等諸多面向。隨著全球帶狀皰疹後神經痛 (PHN) 發病率的不斷上升，這些趨勢正在影響市場的發展方向，並為市場擴張和成長提供新的途徑。

• 遠距醫療整合：遠距醫療也是帶狀皰疹後神經內科 (PHN) 管理的快速成長趨勢，尤其是在遠端監控和疼痛管理方面。隨著線上醫療平台的普及，患者現在可以在家中舒適地與專家遠距會面，而無需親自到場就診。對於農村或醫療資源匱乏地區的患者來說，遠距醫療是一種經濟實惠且便利的解決方案。
• 個人化醫療：個人化醫療在帶狀皰疹後神經痛 (PHN) 管理中發揮著日益重要的作用，使醫療保健專業人員能夠根據患者的個別基因圖譜、病史和具體需求制定個人化治療方案。實施基因組檢測和創建精準醫療療法的趨勢日益成長，正在徹底改變帶狀皰疹後神經痛 (PHN) 的管理。個人化策略正在幫助臨床醫生選擇最佳治療方案，從而改善患者預後並最大限度地減少副作用。
• 再生醫學：再生醫學療法，包括幹細胞療法和組織再生，正在被探索作為帶狀皰疹後神經痛（PHN）的可能療法。這些療法旨在修復神經損傷並恢復正常功能，從而可能為帶狀皰疹後神經痛（PHN）患者帶來長期緩解。該方向的研究尚處於起步階段，但人們預計在不久的將來徹底改變帶狀皰疹後神經痛（PHN）的治療。
• 聯合療法：聯合療法是指藥物療法和非藥物療法相結合的療法，作為治療帶狀皰疹後神經痛 (PHN) 的有效方法，正日益受到重視。透過口服藥物與局部療法、神經刺激裝置或物理治療的結合，患者的疼痛得到有效緩解，生活品質得到提升。隨著醫療機構尋求為帶狀皰疹後神經痛 (PHN) 患者提供更全面的護理，對多模式治療的日益關注正在推動市場成長。
• 非處方藥 (OTC)：非處方 PHN 藥物的研發勢頭日益強勁，患者無需就醫即可治療輕微症狀。 OTC 乳膏、貼片和口服藥物因其便利性和價格實惠而日益流行。這種自我用藥的趨勢在醫療保健資源匱乏的市場尤其重要。

這些新趨勢正在改變帶狀皰疹後神經痛治療市場，提升了治療的可及性，擴大了治療選擇，並為患者提供更個人化的照護。數位化工具的使用、再生醫學的擴展以及聯合療法的實施，正在帶來更有效率、更有效的治療方案。隨著這些趨勢的不斷發展，帶狀皰疹後神經痛（PHN）的治療模式可能會發生重大變化，為患者帶來更好的治療效果，並為市場創造新的成長機會。

帶狀皰疹後神經痛治療市場的最新發展

近年來，帶狀皰疹後神經痛治療市場經歷了巨大的成長。由於該疾病仍然影響著全球數百萬患者，新的治療方法和發展不斷湧現，從而帶來了更好的護理和管理。製藥公司和研究人員正致力於開發新的治療方法，以提高療效和患者預後。在新藥上市、尖端技術和改進的治療方法的推動下，市場正在經歷轉型，以緩解帶狀皰疹後神經痛（PHN）特有的殘疾疼痛。

• 藥物研發進展：近年來，帶狀皰疹後神經痛的新藥研發取得了顯著進展。辣椒素貼片和長效鴉片類藥物等新藥的問世，顯著改變了帶狀皰疹後神經痛的治療。這些藥物旨在持續緩解疼痛，副作用較少，從而提高患者的生活品質。對新型藥物輸送系統的研究不斷加強，也有望提高治療效果。
• 非鴉片類疼痛療法的興起：非鴉片類療法作為一種比鴉片類藥物更安全的帶狀皰疹後神經痛（PHN）治療方案，正日益受到青睞。利多卡因、加巴噴丁和普瑞巴林等藥物已被證明能有效緩解神經痛，且無鴉片類藥物的危害。由於對鴉片類藥物依賴性和副作用的擔憂，市場對這些療法的接受度正在成長，這推動了對非鴉片類療法的需求。
• 遠距醫療與治療方案的整合：遠距醫療極大地改變了帶狀皰疹後神經痛（PHN）的治療。遠距醫療平台如今已被廣泛用於提供遠距會診，使患者能夠更好地管理自體病情。這不僅拓寬了醫療服務管道，尤其惠及農村地區或醫療資源匱乏的患者，也方便了患者病情的監測和治療方案的即時調整。
• 神經調節技術的進展：神經調節療法，包括經顱磁刺激 (TMS) 和脊髓刺激，已在治療帶狀皰疹後神經痛 (PHN) 方面顯示出良好的療效。這些療法透過改變神經活動來減輕疼痛感知。隨著這些技術日益精細化和微創化，它們正被整合到治療方案中，為患者在傳統藥物治療無效時提供替代療法。
• 個人化醫療策略：個人化醫療日益受到重視，這有助於根據患者個體情況量身定做帶狀皰疹後神經性神經痛 (PHN) 治療方案。基因研究的突破使臨床醫生能夠根據患者的基因組成選擇最佳治療方案。這使得治療方案更加精準高效，從而增強疼痛緩解效果並減少副作用。

這些進展正在徹底改變帶狀皰疹後神經痛的治療方案，為患者提供更有效率、更安全、更個人化的治療方案。新的治療方法和創新正在增強帶狀皰疹後神經痛（PHN）的整體管理，減輕那些曾經幾乎沒有其他選擇的患者所遭受的痛苦。這些進步也代表了醫療保健領域朝著非鴉片類藥物、個人化、技術驅動的解決方案發展的大趨勢，這些解決方案兼顧了療效和患者福祉。

目錄

第1章：執行摘要

第2章：全球帶狀皰疹後神經痛治療市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與課題

第3章：2019年至2031年市場趨勢及預測分析

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球帶狀皰疹後神經痛治療市場趨勢（2019-2024 年）及預測（2025-2031 年）
• 全球帶狀皰疹後神經痛治療市場（按類型）
  • 抗驚厥藥
  • 皮膚貼片
  • 其他
• 全球帶狀皰疹後神經痛治療市場（按應用）
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第4章：2019 年至 2031 年各地區市場趨勢及預測分析

• 全球帶狀皰疹後神經痛治療市場（按地區）
• 北美帶狀皰疹後神經痛治療市場
  • 北美市場類型：抗驚厥藥、皮膚貼片及其他
  • 北美市場按應用分類：醫院藥房、網路藥房和零售藥房
• 歐洲帶狀皰疹後神經痛治療市場
  • 歐洲市場類型：抗驚厥藥、皮膚貼片及其他
  • 歐洲市場按應用分類：醫院藥房、網路藥房和零售藥房
• 亞太地區帶狀皰疹後神經痛治療市場
  • 亞太地區市場類型：抗驚厥藥、皮膚貼劑及其他
  • 亞太地區市場按應用分類：醫院藥房、網路藥房和零售藥房
• 其他帶狀皰疹後神經痛治療市場
  • 其他市場類型：抗驚厥藥、皮膚貼片及其他
  • 其他市場（按應用分類）：醫院藥房、網路藥房和零售藥房

第5章：競爭對手分析

• 產品組合分析
• 營運整合
• 波特五力分析

第6章：成長機會與策略分析

• 成長機會分析
  • 全球帶狀皰疹後神經痛治療市場按類型分類的成長機會
  • 全球帶狀皰疹後神經痛治療市場的成長機會（按應用）
  • 全球帶狀皰疹後神經痛治療市場各區域的成長機會
• 全球帶狀皰疹後神經痛治療市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球帶狀皰疹後神經痛治療市場產能擴張
  • 全球帶狀皰疹後神經痛治療市場的合併、收購和合資企業
  • 認證和許可

第7章：主要參與者的公司簡介

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

The future of the global post herpetic neuralgia treatment market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. The global post herpetic neuralgia treatment market is expected to grow with a CAGR of 4.0% from 2025 to 2031. The major drivers for this market are the rising incidence of shingles, the growing awareness of post-herpetic neuralgia, and the increasing availability of advanced treatment options.

• Lucintel forecasts that, within the type category, anticonvulsant is expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is witnessing some emerging trends that are revolutionizing patient care and treatment. These trends vary from technological advancements to changes in patient behavior and treatment paradigms. With an increasing incidence of PHN across the globe, these trends are influencing the path of the market and presenting new avenues for expansion and growth.

• Telemedicine Integration: Telemedicine is also a fast-growing trend for PHN management, particularly for remote monitoring and pain management. As online health platforms proliferate, patients can now remotely meet with specialists in the comfort of their own homes without requiring in-person consultations. Telemedicine is an affordable and convenient solution for patients in rural or underserved locations.
• Personalized Medicine: Personalized medicine is increasingly playing a vital role in the management of PHN, enabling healthcare professionals to customize therapies in accordance with the patient's individual genetic profiles, history, and precise needs. The increasing trend of implementing genomic testing and creating precision medicine therapies is revolutionizing PHN management. Personalized strategies are assisting clinicians in the selection of the best treatments, thereby enhancing patient outcomes and minimizing side effects.
• Regenerative Medicine: Regenerative medicine treatments, including stem cell therapy and tissue regeneration, are being explored as possible PHN therapies. These treatments seek to heal nerve injury and restore normal function, which might provide long-term relief for PHN sufferers. Studies in this direction are in nascent stages, but there is hope that regenerative therapies will revolutionize the treatment of PHN in the near future.
• Combination Therapies: Combination therapies, involving a combination of pharmacological and non-pharmacological therapies, are picking up steam as effective approaches to treating PHN. With the combination of oral drugs and topical therapies, nerve stimulation devices, or physical therapy, patients show improved pain relief and enhanced quality of life. The growing focus on multi-modal treatments is fueling market growth as providers seek to provide more holistic care to PHN patients.
• Over-the-Counter (OTC) Products: There is increasing momentum in the creation of over-the-counter PHN drugs so that patients can treat minor symptoms without seeing a doctor. OTC creams, patches, and oral medications are becoming popular due to convenience and affordability. This trend toward self-medication is particularly critical in markets where access to health care is restricted.

These new trends are transforming the post herpetic neuralgia treatment market by enhancing accessibility, expanding treatment options, and offering more individualized care to patients. The use of digital tools, the expansion of regenerative medicine, and the implementation of combination therapies are leading to more efficient and effective treatments. As these trends continue to evolve, the treatment landscape for PHN will likely undergo significant changes, offering better outcomes for patients and creating new opportunities for growth in the market.

Recent Developments in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market has witnessed massive growth in the recent past years. With the condition still impacting millions of patients globally, new treatments and developments are coming into view, resulting in better care and management. Drug firms as well as researchers are concentrating on new treatment methodologies, enhancing efficacy, and patient outcomes. The market is experiencing transformation fueled by novel drug launches, cutting-edge technologies, and improved therapeutic approaches to alleviate the disabling pain that characterizes PHN.

• Progress in Drug Development: In the last few years, there has been substantial advancement in the new drug development for Post-Herpetic Neuralgia. The introduction of new drugs such as capsaicin patches and long-acting opioids has significantly changed the treatment of PHN. These drugs target sustained relief from pain with less side effect, enhancing the quality of life in patients. Increased research into new drug delivery systems also holds the potential for enhancing treatment effectiveness.
• Emergence of Non-Opioid Pain Therapies: Non-opioid therapies are gaining momentum as a more secure option than opioid-based treatments for PHN. Drugs such as lidocaine, gabapentin, and pregabalin proved effective in alleviating nerve pain without the hazards of opioids. The market is experiencing growth in the acceptance of these therapies due to fears of opioid dependency and side effects fueling demand for non-opioid therapies.
• Telemedicine Integration in Treatment Plans: Telemedicine has transformed the treatment of PHN dramatically. Telemedicine platforms are now widely utilized to offer remote consultations, enabling patients to better manage their condition. This has opened up access to healthcare, particularly for rural or underserved patients, and has facilitated easier monitoring of patient progress and real-time adjustment of treatments.
• Advances in Neuromodulation Techniques: Neuromodulation therapies, including transcranial magnetic stimulation (TMS) and spinal cord stimulation, have shown promising results in treating PHN. These therapies work by altering nerve activity to reduce pain perception. As these techniques become more refined and less invasive, they are being integrated into treatment regimens, offering patients alternatives when traditional medications fail.
• Personalized Medicine Strategy: The growing emphasis on personalized medicine is assisting in tailoring PHN therapies to the individual. Breakthroughs in genetic research are making it possible for clinicians to select the most optimal therapies according to a patient's genetic makeup. This enables more precise and efficient treatment regimens, resulting in enhanced pain relief and reduced side effects.

These advancements are revolutionizing the post herpetic neuralgia treatment scenario by providing patients with more efficient, safer, and customized options. New treatments and innovations are enhancing the overall management of PHN, alleviating suffering for those who once had few alternatives. These advancements also represent a larger trend within the healthcare sector towards non-opioid, customized, and technology-driven solutions that balance both efficacy and patient welfare.

Strategic Growth Opportunities in the Post Herpetic Neuralgia Treatment Market

Post herpetic neuralgia treatment market is witnessing a number of growth prospects fueled by innovations, technological breakthroughs, and growing demand for improved solutions. The market is growing as increasing targeted therapies, developments in the mode of delivery of treatments, and growing emphasis on patient-centric care are providing opportunities to grow. Pharmaceutical organizations, healthcare providers, and investors are looking into major applications that will improve treatment and patient outcomes.

• Innovations in Topical Therapies: Topical therapies, including lidocaine and capsaicin patches, are emerging as a major growth opportunity in the PHN market. These treatments deliver localized pain relief with few systemic side effects and are thus a desirable choice for patients who want alternatives to oral drugs. Ongoing innovations in formulation and delivery systems will increase the efficacy and market penetration of topical therapies.
• Growth of Non-Opioid Therapeutics: With increasing need for non-opioid treatment of pain, there is evidently a chance of developing drugs which address the basic mechanisms of PHN without opioid dependency. Emerging molecules like newer anticonvulsants and antidepressants are being researched for better control of nerve pain and provide a new growth opportunity for pharmaceutical companies.
• Telemedicine and Remote Monitoring Solutions: Expansion of telemedicine and digital health technologies is providing opportunities to enhance patient care and treatment outcomes for PHN. Remote monitoring devices, wearable sensors, and mobile health apps can monitor symptoms and modify treatments in real time. This enhances the convenience and accessibility of PHN care, particularly for patients who live in remote locations or have mobility problems.
• Enhanced Neuromodulation Devices: The neuromodulation device market, including spinal cord stimulators and peripheral nerve stimulators, is likely to grow substantially. These devices provide a non-pharmacologic treatment option for PHN and are becoming increasingly popular due to their efficacy and decreased side-effect profile. Increased research and development will further enhance these devices, making them more precise and patient beneficial.
• Personalized Medicine in Pain Relief: Personalized medicine offers a sizeable growth opportunity through the targeting of treatments with genetic and molecular patient profiling. This strategy should maximize pain relief for PHN patients, so that the correct treatments are used for each. The incorporation of genomic information into treatment plans will enhance efficacy and reduce side effects, making personalized therapies a central market driver.

These growth opportunities reflect the trend towards more personalized, non-opioid, and technology-based solutions in the management of post herpetic neuralgia. As these applications mature, they not only enhance patient outcomes but also increase the scope of available treatment options. This makes the market more competitive and diverse, with increased emphasis on patient-centric care, which will fuel market growth in the next few years.

Post Herpetic Neuralgia Treatment Market Driver and Challenges

The post herpetic neuralgia treatment market is driven by a wide range of factors involving technology advancements, economic factors, and regulatory forces. Although many drivers are dominating the growth of the market, some obstacles such as regulatory barriers and treatment constraints are also affecting the rate of growth. Knowledge of these drivers and challenges is essential for stakeholders to steer the changing landscape of PHN treatment successfully.

The factors responsible for driving the post herpetic neuralgia treatment market include:

1. Growing Incidence of Herpes Zoster: One of the key drivers of demand for PHN treatments is the growing incidence of Herpes Zoster (shingles). With the aging of the global population, the number of cases of shingles and its complications, such as PHN, is on the rise. This is fueling the demand for effective treatments and therapies, leading to the expansion of the PHN treatment market.

2. Technological Advances in Treatment Modalities: The quick developments in neuromodulation technologies, customized medicine, and drug delivery devices are having a positive impact on the PHN treatment market. The new developments are making treatments more precise and effective, enhancing patient outcomes, and driving market growth. R&D is being heavily invested in by companies to introduce advanced technologies to the market.

3. Increased Awareness and Rising Diagnosis Rates: Public awareness regarding PHN and its effect on the quality of life of patients has increased over time. Increasing awareness is resulting in early diagnosis and treatment, which is fueling the demand for therapeutic solutions. Physicians are also learning to identify PHN at an early stage, further contributing to market growth.

4. Demand for Non-Opioid Pain Management: Owing to increasing fears over opioid addiction and dependence, demand for non-opioid pain management practices has picked up quite well. Increasing need for substitute treatment methods providing potent pain relief with minimal potential for addiction is pushing the usage of non-opioid treatment in PHN, stimulating the market growth.

5. Government Programs and Funding: Governments globally are realizing the cost of chronic pain conditions such as PHN, and many are providing incentives and funding to stimulate research on new treatments. This funding is stimulating innovation and speeding up the creation of better therapies.

Challenges in the post herpetic neuralgia treatment market are:

1. Regulatory and Approval Delays: One of the biggest challenges in the PHN treatment market is the long and complex approval process for emerging therapies. Delays in regulation can hinder the timely release of new and innovative therapies, limiting market growth and patient access to leading-edge therapies.

2. Limited Efficacy of Current Therapies: Although a variety of PHN treatments are currently available, patients still suffer from inadequate pain relief. The failure of universally effective therapies is one of the biggest challenges, and as a result, drug treatments fall short, creating unmet medical needs and ongoing demand for more effective treatments.

3. Cost of Treatment: The expensive nature of some PHN treatments, especially advanced neuromodulation equipment and customized therapies, continues to be a barrier for most patients. In other areas, insufficient insurance coverage and budgetary issues deter patients from obtaining the best treatment, which influences market adoption levels.

The post herpetic neuralgia market for treatment is expanding through rising incidence, technological innovation, and transition to pain management through non-opioid options. Despite these, limitations such as slow regulatory processes, limited effectiveness of existing therapies, and high costs of treatment are currently major impediments. Addressing these through innovation, changes in regulations, and enhanced affordability will be essential to further growth in the market and the creation of more effective PHN treatments.

List of Post Herpetic Neuralgia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post herpetic neuralgia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post herpetic neuralgia treatment companies profiled in this report include-

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

Post Herpetic Neuralgia Treatment Market by Segment

The study includes a forecast for the global post herpetic neuralgia treatment market by type, application, and region.

Post Herpetic Neuralgia Treatment Market by Type [Value from 2019 to 2031]:

• Anticonvulsants
• Skin Patch
• Other

Post Herpetic Neuralgia Treatment Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Post Herpetic Neuralgia Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Post Herpetic Neuralgia Treatment Market

In recent years, the post herpetic neuralgia treatment market has seen considerable growth in different countries like the United States, China, Germany, India, and Japan. The market has been driven by the growth in both pharmaceuticals and other treatments that address the chronic pain of PHN. Major growth drivers of this market include an aging population, greater knowledge about PHN, and innovation in new drugs and technologies. Challenges in the availability of treatment, cost, and regulatory barriers continue, specifically in developing countries. Technological advancements and changing patient requirements are both influencing the growth of the market.

• United States: The United States is still a dominant force in the post herpetic neuralgia Treatment Market, led by developments in pain management therapies. New approvals of drugs, especially new analgesics and nerve-directed treatments, have increased the range of treatments available to patients. The U.S. is also still at the forefront of the use of transcutaneous electrical nerve stimulation (TENS) devices and other non-pharmacological therapies. Furthermore, the growing incidence of herpes zoster infections and heightened awareness of PHN have also stimulated demand for therapies. Healthcare infrastructure and insurance for such treatments also boost market growth in the region.
• China: The post herpetic neuralgia Treatment Market in China is increasing at a rapid pace due to a growing healthcare industry and heightened awareness of PHN. The Chinese government has been enhancing healthcare access, which is predicted to increase the uptake of treatments. Access to sophisticated pain treatment, though, is still challenging in rural China. While drugs rule the marketplace, traditional Chinese medicine (TCM) therapy is being added to treatment plans more and more, with expanding interest in herbal and acupuncture therapies. This blend of conventional and new medicine is anticipated to be instrumental in the development of the market.
• Germany: Germany's post herpetic neuralgia Treatment Market is helped by its highly developed healthcare system and strong pharmaceutical sector. There has been an increase in new drug approvals and availability that help ease PHN pain, including topical and anticonvulsant medications. Germany also places significant emphasis on pain management research, leading to the establishment of non-invasive therapies such as neuromodulation and TENS devices. With the increasing population of the elderly, the need for good PHN treatments is bound to be on the rise. The robust healthcare base also provides improved access to these treatments, fueling market growth.
• India: India is confronted with an upsurge in PHN prevalence, mainly caused by a rise in shingles. The healthcare system of the country has been changing very fast, and treatment for PHN is now more accessible. Affordability is a major issue still, especially in rural India. New trends in the Indian market are the launch of generic forms of newer pain management medications, which have made these treatments affordable. In addition, campaigns regarding PHN and its treatment are picking pace, which may result in more patient interaction and treatment compliance, hence further driving market growth.
• Japan: Japan has a robust healthcare infrastructure, and the treatment scenario for post herpetic neuralgia is progressing steadily. Japan's market has experienced a rise in the use of sophisticated pain management therapies, such as nerve-blocking therapy and the use of technology in pain management. Japan also takes the lead in conducting research into novel drug therapy for PHN, with emphasis on efficacy and safety. The government has been initiating a move to get these drugs more widely available to the elderly, so that effective pain management is accessible to the increasing population of PHN patients.

Features of the Global Post Herpetic Neuralgia Treatment Market

Market Size Estimates: Post herpetic neuralgia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Post herpetic neuralgia treatment market size by type, application, and region in terms of value ($B).

Regional Analysis: Post herpetic neuralgia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the post herpetic neuralgia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post herpetic neuralgia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the post herpetic neuralgia treatment market by type (anticonvulsants, skin patch, and other), application (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post Herpetic Neuralgia Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Post Herpetic Neuralgia Treatment Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Post Herpetic Neuralgia Treatment Market by Type
  • 3.3.1: Anticonvulsants
  • 3.3.2: Skin Patch
  • 3.3.3: Other
• 3.4: Global Post Herpetic Neuralgia Treatment Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Online Pharmacies
  • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Post Herpetic Neuralgia Treatment Market by Region
• 4.2: North American Post Herpetic Neuralgia Treatment Market
  • 4.2.1: North American Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.3: European Post Herpetic Neuralgia Treatment Market
  • 4.3.1: European Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.3.2: European Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.4: APAC Post Herpetic Neuralgia Treatment Market
  • 4.4.1: APAC Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.5: ROW Post Herpetic Neuralgia Treatment Market
  • 4.5.1: ROW Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Application
  • 6.1.3: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Region
• 6.2: Emerging Trends in the Global Post Herpetic Neuralgia Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Arbor Pharma
• 7.3: Assertio Therapeutics
• 7.4: Endo Pharma
• 7.5: Teikoku Pharma
• 7.6: Teva
• 7.7: Mylan